Prescribing information and Adverse event reporting can be found at the bottom of the page

Brand Navigation Banner

Search Header


Helping your patients make the right choice

With rising abortion rates, particularly among all ages 25 and above, the largest increase are amongst women aged 30. Therefore, there is a clear need to offer the most effective contraceptive methods.1 In a quantitative survey of over 430 women and their experiences of unintended pregnancy and abortion, over half were using contraception at the time they became pregnant.2 Long-acting methods can be the most effective form of contraception because they do not rely on user compliance.3


Here you will find resources to guide conversations with your patients, helping to identify which is the most suitable contraception for them.

Use the Range of contraception leaflet with your patients to discuss the different options available and to help them make an informed decision on which contraception is best for them.


Pill compliance is a common struggle for women1

For every 100 women that choose to take the pill this year, nine could become pregnant due to missed-pill moments.2 Long-acting methods such as intrauterine systems (IUS) offer birth control with the highest available efficacy and are one of the most effective contraceptive methods because their effectiveness is independent of user compliance.3


Pill compliance

Choose an IUS that best meets her needs

13.5mg intrauterine delivery system (levonorgestrel)
19.5mg intrauterine delivery system (levonorgestrel)
52mg intrauterine delivery system (levonorgestrel)
Indication Contraception for up to 3 years Contraception for up to 5 years Contraception for up to 5 years Treatement of HMB for up to 5 years endometrial protection during HRT for 4 years
Pearl Index (efficacy) Year 1:0.41
3-years: 0:33
Year 1: 0.16
5-years: 0.29
Year 1: 0.2
Years 5: 0.144
Contraceptive failure rate 0.4% at 1 year
0.9% over 3 years
0.2% at 1 year
1.4% over 5 years
0.2% at 1 year
0.7% over 5 years
Total levonorgestrel (LNG) content (mg) 13.5 19.5 52
Average in vivo LNG release rate over the first year of use 8 μg/24 hours 12.6 μg/24 hours2 20 μg/24 hours*
% of women experiencing amenorrhoea and infrequent bleeding at 1 year post insertion Amenorrhoea: 6%
infrequent bleeding: 20%
Amenorrhoea: 12%
infrequent bleeding: 26%
Amenorrhoea: 16%
infrequent bleeding: 57%
T-frame size (mm) 28 × 30 28 × 30 32 × 324
Placement tube diameter size (mm) 3.8 3.8 4.4
Colour of monofilament threads Brown Blue Brown
Differentiator in imaging techniques:silver ring Improved visibility on ultrasound Improved visibility on ultrasound -

If you are a fitter of IUS, visit Fitter resources which covers all the practical aspects of the IUS/IUD fitting process, including preparation and loading advice.

Kyleena case studies

PP-PF-WHC-GB-1033 May 2022

Search Footer

Reporting adverse events and quality complaints


Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Bayer plc.


If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 011820‍63500 or email:


Further information is available on the “contact” tab at